Concepedia

Robert Faltus

RF

Statistics

Publications

6

Citations

143

H-Index

6

Active since

2014

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Robert Faltus is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, leucine-rich repeat receptor-like kinases, and potency optimization.

Publications per year

2014–2023

6

Publications

6

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors

Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar et al. · Journal of Medicinal Chemistry · 2021 · 42 citations · Full text

, , +17

Development and optimization of a high-throughput micro-computed tomography imaging method incorporating a novel analysis technique to evaluate bone mineral density of arthritic joints in a rodent model of collagen induced arthritis

Raquel Sevilla, Francisco Cruz, Chi‐Sung Chiu et al. · Bone · 2014 · 27 citations · Full text

, , +17

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 <i>H</i> -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease

David A. Candito, Vladimir Simov, Anmol Gulati et al. · Journal of Medicinal Chemistry · 2022 · 24 citations · Full text

, , +15

Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson’s Disease

Solomon D. Kattar, Anmol Gulati, Kaila A. Margrey et al. · Journal of Medicinal Chemistry · 2023 · 19 citations · Full text

, , +17

Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis

Kalyan Chakravarthy, Robert Faltus, Gain Robinson et al. · BMC Musculoskeletal Disorders · 2014 · 17 citations · Full text

, , +16

1–5 of 6